#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #Ameet Mallik

ADC Therapeutics to Showcase Innovations at November Investor Conferences

ADC Therapeutics SA (NYSE: ADCT), a pioneering force in the global biopharmaceutical landscape, is gearing up to participate in two important investor conferences during November 2026. These events mark a significant opportunity for the company to engage with investors and highlight its advancements in the field of antibody drug conjugates, particularly focusing on its flagship product, ZYNLONTA® (loncastuximab tesirine-lpyl).

Upcoming Conferences

1. Guggenheim Third Annual Healthcare Innovation Conference
- Date: Tuesday, November 10, 2026
- Time: 1:30 p.m. EST
- Format: Fireside Chat
- Speaker: Ameet Mallik, CEO
- Location: Boston, MA
- Webcast Registration: Here

2. Jefferies Global Healthcare Conference
- Date: Thursday, November 19, 2026
- Time: 1:00 - 1:25 p.m. GMT
- Format: Fireside Chat
- Speaker: Ameet Mallik, CEO
- Location: London, England
- Webcast Registration: Here

Live webcasts of both presentations will be available via ADC Therapeutics’ website, allowing a wider audience to gain insights into the company’s strategic initiatives and product developments. Additionally, replays of these sessions will be accessible for about 30 days post-event.

About ADC Therapeutics and ZYNLONTA

Established and headquartered in Lausanne, Switzerland, ADC Therapeutics is recognized for its cutting-edge work in antibody drug conjugates. These specialized therapeutics aim to revolutionize cancer treatment by delivering targeted therapies directly to cancer cells. The company's flagship product, ZYNLONTA, has garnered noteworthy attention after receiving accelerated approval from the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma following multiple lines of systemic therapy.

As ADC Therapeutics continues to expand the applications of ZYNLONTA, it is also exploring its use in combination therapies and earlier treatment settings, which could significantly impact patient outcomes in oncology. The CEO, Ameet Mallik, is often at the forefront of these discussions, shedding light on critical developments and future plans during investor interactions.

The Future of ADC Therapeutics

In a landscape ripe with transformation, ADC Therapeutics stands out due to its commitment to innovation and patient-focused initiatives. The company's ability to navigate the complexities of regulatory environments, while advancing its product pipeline, showcases its resilience and adaptability in a rapidly evolving field. With anticipated revenue growth and strategic partnerships on the horizon, ADC Therapeutics is poised to play a leading role in the future of targeted cancer therapies.

As November approaches, interest in the company’s presentations is expected to increase, especially among investors keen to learn more about ADC Therapeutics’ strategic direction and groundbreaking therapies that could redefine treatment approaches for cancer patients worldwide.

In conclusion, with these upcoming conferences, ADC Therapeutics aims not just to present data but also to forge connections with stakeholders who resonate with their mission of enhancing patient care through precise, innovative therapeutic solutions.